John Maraganore joins up with ProQR as strategic advisor; Servier nabs priority review for Tibsovo sNDA
After a month-long break from advisory appointments, John Maraganore is once again being tapped to join another biotech.
The RNA-focused startup announced Maraganore’s appointment this morning, with the Alnylam founding CEO joining up as a strategic advisor to ProQR’s supervisory board.
Monday’s move comes a few weeks after the biotech’s lead candidate for the rare genetic eye disease, Leber congenital amaurosis, had shown no difference between placebo and any other efficacy measures. Maraganore said in a statement that he first met ProQR CEO Daniel de Boer more than a decade ago through former Genzyme CEO Henri Termeer, before his passing in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.